Recent Updates
Recently added Catalysts

Eloralintide and Tirzepatide

Phase 3

Overweight | Small molecule | Metabolic |Eli Lilly and Company|Last Updated: Jun 4, 2026

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
RandomizedDouble-BlindCONTROLLEDDMCBiomarker
Total Trials3
Total Enrollment2,123
FDA Designations
No designations recorded
Clinical Trials (3)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT07392190A Study of Eloralintide (LY3841136) in Participants With Persistent Obesity Who Are Treated With a Weekly IncretinPHASE3 RECRUITING 900 — — Feb 10, 2026Jul 1, 2028Jun 4, 2026180 United States, Australia +12
NCT07282600A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 DiabetesPHASE3 RECRUITING 1,035 — — Dec 15, 2025Feb 1, 2028Jun 4, 2026159 United States, Argentina +12
NCT06916065A Study of Eloralintide (LY3841136) and Eloralintide With Tirzepatide in Participants With Overweight or ObesityPHASE1 COMPLETED 188 — — Apr 9, 2025Jan 19, 2026Jan 30, 20263 United States
Unlock Drug Trial Details
Study Endpoints
Primary Endpoints
Percent Change from Baseline in Body Weight
Baseline, Week 64
Cohorts A and B: Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve (AUC) of Eloralintide and Tirzepatide
Day 106 Predose to Approximately Week 26

PK: AUC of Eloralintide and Tirzepatide

Cohorts A and B: PK: Maximum Concentration (Cmax) of Eloralintide and Tirzepatide
Day 106 Predose to Approximately Week 26

PK: Cmax of Eloralintide and Tirzepatide

Cohorts C and D: PK: AUC of Eloralintide and Tirzepatide
Baseline Up to Approximately Week 11

PK: AUC of Eloralintide and Tirzepatide

Cohorts C and D: PK: Cmax of Eloralintide and Tirzepatide
Baseline Up to Approximately Week 11

PK: Cmax of Eloralintide and Tirzepatide

Cohorts E and F: PK: AUC of Eloralintide
Day 8 Predose Up to Approximately Week 12

PK: AUC of Eloralintide

Cohorts E and F: PK: Cmax of Eloralintide
Day 8 Predose Up to Approximately Week 12

PK: Cmax of Eloralintide

Number of Participants with One or More Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration
Baseline Up to Approximately Week 26

A summary of TEAEs and SAEs regardless of causality, will be reported in the Reported Adverse Events module

Secondary Endpoints
Change from Baseline in Waist Circumference
Baseline, Week 64
Percent Change in Baseline in Triglycerides
Baseline, Week 64
Change from Baseline in Systolic Blood Pressure
Baseline, Week 64
Unlock Study Endpoints
Study Design & Arms
AllocationRANDOMIZED
MaskingDOUBLE
ModelPARALLEL
PurposeTREATMENT
Treatment Arms
ArmTypeDescription
Eloralintide Dose 1EXPERIMENTALParticipants will receive eloralintide subcutaneously (SC)
Eloralintide Dose 2EXPERIMENTALParticipants will receive eloralintide SC
Eloralintide Dose 3EXPERIMENTALParticipants will receive eloralintide SC
Eloralintide Dose 4EXPERIMENTALParticipants will receive eloralintide SC
PlaceboPLACEBO_COMPARATORParticipants will receive placebo SC
Eloralintide and Tirzepatide-Cohorts A-DEXPERIMENTALEloralintide and Tirzepatide administered subcutaneously (SC)
Eloralintide-Cohorts E and FEXPERIMENTALEloralintide administered SC
Interventions
NameTypeDescription
EloralintideDRUGAdministered SC
PlaceboDRUGAdministered SC
Eloralintide and TirzepatideDRUGAdministered SC
Unlock Study Design Details
Eligibility Criteria
Age Range18 Years — N/A
SexALL
Healthy VolunteersNo
Study Sites180

Inclusion Criteria: * Are on stable incretin therapy at screening * With persistent obesity or overweight defined as: * ≥30 kg/m2 OR * ≥27 kg/m2 with at least one existing obesity related complication at screening: * hypertension * dyslipidemia * obstructive sleep apnea * card...

Countries:United StatesAustraliaBelgiumBrazilChinaCzechiaIndiaIsraelJapanMexicoPuerto RicoRomaniaSpainTaiwanArgentinaGermanyPolandSlovakiaSouth Korea
Unlock Eligibility Criteria
Recent Changes (Last 90 Days)
LOWJun 4, 2026NCT07282600lastUpdatePostDate: changed
LOWJun 4, 2026NCT07392190lastUpdatePostDate: changed
LOWJun 4, 2026NCT07282600lastUpdatePostDate: changed
LOWJun 4, 2026NCT07392190lastUpdatePostDate: changed
LOWJun 4, 2026NCT07282600lastUpdatePostDate: changed
LOWJun 4, 2026NCT07392190lastUpdatePostDate: changed
LOWJun 4, 2026NCT07282600lastUpdatePostDate: changed
LOWJun 4, 2026NCT07392190lastUpdatePostDate: changed
LOWMay 26, 2026NCT07282600primaryCompletionDate: changed
LOWMay 26, 2026NCT07392190primaryCompletionDate: changed
LOWMay 24, 2026NCT07282600studyFirstPostDate: changed
LOWMay 24, 2026NCT07392190studyFirstPostDate: changed